The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance

Haematologica

Volumn 95, Issue 7, 2010, Pages 1221-1225

  Ross, Fiona M ^a   Chiecchio, Laura ^a   Dagrada, Gianpaolo ^a   Protheroe, Rebecca K M ^a   Stockley, David M ^a   Harrison, Christine J ^b   Cross, Nicholas Cp ^a   Szubert, Alex J ^c   Drayson, Mark T ^d   Morgan, Gareth J ^e  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Chromosome abnormality; Disease progression; MGUS; Myeloma; Plasma cell

Indexed keywords

IMMUNOGLOBULIN A; TRANSCRIPTION FACTOR MAF;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; BONE DISEASE; BONE MARROW; CHROMOSOME 1Q; CHROMOSOME DELETION 13; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 16; CHROMOSOME TRANSLOCATION 20; CHROMOSOME TRANSLOCATION 4; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MUTATIONAL ANALYSIS; MYELOMA; OUTCOME ASSESSMENT; PLASMA CELL DYSCRASIA; POLYPLOIDY; PROGNOSIS; DISEASE COURSE; GENE TRANSLOCATION; GENETICS; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; PROGNOSIS; TRANSLOCATION, GENETIC;

EID: 77954516403     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.016329     Document Type: Article

References (24)

1. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005; 23(26):6333-8.
2. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003; 101(11):4569-75.
3. Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T, et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell. 2004;5(2):191-9.
4. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109(8):3489-95.
5. Cremer FW, Bila J, Buck I, Kartal M, Hose D, Ittrich C, et al. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer. 2005;44(2):194-203.
6. Gutierrez NC, Castellanos MV, Martin ML, Mateos MV, Hernandez JM, Fernandez M, et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia. 2007;21(l):143-50.
7. Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ, et al. In multiple myeloma, t(4;14)(pl6;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood. 2003;101(4):1520-9.
8. Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Litzow MR, Henderson KJ, et al. Clinical implications of t(ll;14)(ql3;q32), t(4;14)(pl6.3;q32), and -17pl3 in myeloma patients treated with high-dose therapy Blood. 2005;106(8): 2837-40.
9. Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, Harousseau JL, et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood. 2002;99(6):2185-91.
10. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564-9.
11. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91(1):3-21.
12. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113(22):5412-7.
13. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009;113(22):5418-22.
14. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2(3):175-87.
15. Malgeri U, Baldini L, Perfetti V, Fabris S, Vignarelli MC, Colombo G, et al. Detection of t(4;14)(pl6.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts. Cancer Res. 2000;60(15):4058-61.
16. Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar SV, Hoyer JD, Lust JA, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002;100(4):1417-24.
17. Van Wier SA, Ahmann GJ, Henderson KJ, Greipp PR, Rajkumar SV, Larson D, et al. The t(4;14) is present in patients with early stage plasma cell proliferative disorders including MGUS and smoldering multiple myeloma (SMM). Blood 106[11], 1545.1-11-2005.
18. Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. HematolJ. 2004;5(3):285.
19. Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Cocks K, et al. The addition of thalidomide to the induction treatment of newly presenting myeloma patients increases the CR rate which is likely to translate into improved PFS and OS. Blood. 2009, 114(22):#352.
20. Ross FM, Ibrahim AH, Vilain-Holmes A, Winfield MO, Chiecchio L, Protheroe RK, et al. Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma. Leukemia. 2005;19(9):1634-42.
21. Chiecchio L, Protheroe RK, Ibrahim AH, Cheung KL, Rudduck C, Dagrada GP, et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia. 2006; 20(9):1610-7.
22. Wuilleme S, Robillard N, Lode L, Magrangeas F, Beris H, Harousseau JL, etal. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia 2005; 19(2):275-8.
23. Chng WJ, Glebov O, Bergsagel PL, Kuehl WM. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol. 2007;20(4):571-96.
24. Rosinol L, Carrio A, Blade J, Queralt R, Aymerich M, Qbeira MT, et al. Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma. Br J Haematol. 2005;130(5):729-32.